IsoRay, Inc.  

(Public, NYSEMKT:ISR)   Watch this stock  
Find more results for NYSEAMEX:ISR
-0.010 (-1.50%)
Oct 21 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 0.63 - 0.70
52 week 0.55 - 1.65
Open 0.68
Vol / Avg. 92,118.00/89,019.00
Mkt cap 36.58M
P/E     -
Div/yield     -
EPS -0.09
Shares 55.01M
Beta -1.23
Inst. own 8%
Nov 8, 2016
Q1 2017 IsoRay Inc Earnings Release (Estimated) Add to calendar
Sep 13, 2016
Q4 2016 IsoRay Inc Earnings Call
Sep 13, 2016
IsoRay Inc at Rodman & Renshaw Global Investment Conference
Sep 8, 2016
Q4 2016 IsoRay Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2016
Net profit margin -105.76% -98.77%
Operating margin -152.66% -116.12%
EBITD margin - -104.55%
Return on average assets -25.08% -22.92%
Return on average equity -28.08% -25.40%
Employees 41 -
CDP Score - -


350 Hills St Ste 106
RICHLAND, WA 99354-5511
United States - Map
+1-509-3751202 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


IsoRay, Inc. is a medical technology company. The Company, through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds. Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor. The Cs-131 includes radioisotope in the treatment of all malignant tumors, such as prostate cancer, brain cancer, breast cancer, colorectal cancer, gynecological cancer, lung cancer, liver cancer, ocular melanoma and pancreatic cancer. The Company's Proxcelan Cesium-131 seed is classified as a Class II device.

Officers and directors

Thomas C LaVoy Chairman of the Board, Chief Executive Officer
Age: 55
Bio & Compensation  - Reuters
Brien Ragle Chief Financial Officer
Age: 46
Bio & Compensation  - Reuters
William Cavanagh III Chief Operating Officer
Age: 50
Bio & Compensation  - Reuters
Michael W. McCormick Director
Bio & Compensation  - Reuters
Philip J. Vitale M.D. Independent Director
Age: 68
Bio & Compensation  - Reuters